Switch theme
Sign up to access all valuation multiples
Yuhan Corp is a pharmaceutical company. The core business of the company is classified as primary and specialty care, dietary supplements, household and animal care, and contract manufacturing of active pharmaceutical ingredients. The company offers one-stop custom synthesis services from research and development to commercial production of active pharmaceutical products (APIs) and intermediates for the following disease treatments: antivirals (HCV and HIV), antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds for international markets.
1926
n/a
LTM Revenue $1.4B
LTM EBITDA $93.2M
$5.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Yuhan has a last 12-month revenue of $1.4B and a last 12-month EBITDA of $93.2M.
In the most recent fiscal year, Yuhan achieved revenue of $1.4B and an EBITDA of $94.8M.
Yuhan expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Yuhan valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.3B | $1.4B | XXX | XXX | XXX |
| Gross Profit | $353M | $386M | XXX | XXX | XXX |
| Gross Margin | 28% | 27% | XXX | XXX | XXX |
| EBITDA | $126M | $94.8M | XXX | XXX | XXX |
| EBITDA Margin | 10% | 7% | XXX | XXX | XXX |
| Net Profit | $64.8M | $92.7M | XXX | XXX | XXX |
| Net Margin | 5% | 7% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Yuhan's stock price is KRW 113421 (or $77).
Yuhan has current market cap of KRW 8.50T (or $5.8B), and EV of KRW 8.47T (or $5.8B).
See Yuhan trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.8B | $5.8B | XXX | XXX | XXX | XXX | $0.68 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Yuhan has market cap of $5.8B and EV of $5.8B.
Yuhan's trades at 4.0x LTM EV/Revenue multiple, and 61.9x LTM EBITDA.
Analysts estimate Yuhan's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Yuhan and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $5.8B | XXX | XXX | XXX |
| EV/Revenue | 4.1x | XXX | XXX | XXX |
| EV/EBITDA | 60.9x | XXX | XXX | XXX |
| P/E | 120.2x | XXX | XXX | XXX |
| P/E/Growth | 1.7x | XXX | XXX | XXX |
| EV/FCF | -106.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpYuhan's NTM/LTM revenue growth is 9%
Yuhan's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Yuhan's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Yuhan's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Yuhan and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -25% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 16% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 11% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 31% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Yuhan acquired XXX companies to date.
Last acquisition by Yuhan was XXXXXXXX, XXXXX XXXXX XXXXXX . Yuhan acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Yuhan founded? | Yuhan was founded in 1926. |
| Where is Yuhan headquartered? | Yuhan is headquartered in South Korea. |
| Who is the CEO of Yuhan? | Yuhan's CEO is Mr. Wook-je Cho. |
| Is Yuhan publicy listed? | Yes, Yuhan is a public company listed on KRX. |
| What is the stock symbol of Yuhan? | Yuhan trades under 000100 ticker. |
| When did Yuhan go public? | Yuhan went public in 1962. |
| Who are competitors of Yuhan? | Similar companies to Yuhan include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Yuhan? | Yuhan's current market cap is $5.8B |
| What is the current revenue of Yuhan? | Yuhan's last 12-month revenue is $1.4B. |
| What is the current EBITDA of Yuhan? | Yuhan's last 12-month EBITDA is $93.2M. |
| What is the current EV/Revenue multiple of Yuhan? | Current revenue multiple of Yuhan is 4.0x. |
| What is the current EV/EBITDA multiple of Yuhan? | Current EBITDA multiple of Yuhan is 61.9x. |
| What is the current revenue growth of Yuhan? | Yuhan revenue growth between 2023 and 2024 was 11%. |
| Is Yuhan profitable? | Yes, Yuhan is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
